161 related articles for article (PubMed ID: 34272087)
1. Fibrolamellar carcinoma: An entity all its own.
O'Neill AF; Church AJ; Perez-Atayde AR; Shaikh R; Marcus KJ; Vakili K
Curr Probl Cancer; 2021 Aug; 45(4):100770. PubMed ID: 34272087
[TBL] [Abstract][Full Text] [Related]
2. Fibrolamellar Hepatocellular Carcinoma: Comprehensive Review of Diagnosis, Imaging, and Management.
Aziz H; Brown ZJ; Panid Madani S; Kamel IR; Pawlik TM
J Am Coll Surg; 2023 Feb; 236(2):399-410. PubMed ID: 36648268
[TBL] [Abstract][Full Text] [Related]
3. BAP1 mutations define a homogeneous subgroup of hepatocellular carcinoma with fibrolamellar-like features and activated PKA.
Hirsch TZ; Negulescu A; Gupta B; Caruso S; Noblet B; Couchy G; Bayard Q; Meunier L; Morcrette G; Scoazec JY; Blanc JF; Amaddeo G; Nault JC; Bioulac-Sage P; Ziol M; Beaufrère A; Paradis V; Calderaro J; Imbeaud S; Zucman-Rossi J
J Hepatol; 2020 May; 72(5):924-936. PubMed ID: 31862487
[TBL] [Abstract][Full Text] [Related]
4. Exploring the molecular pathogenesis, diagnosis and treatment of fibrolamellar hepatocellular carcinoma: A state of art review of the current literature.
Alshareefy Y; Shen CY; Prekash RJ
Pathol Res Pract; 2023 Aug; 248():154655. PubMed ID: 37429175
[TBL] [Abstract][Full Text] [Related]
5. Molecular profiling and analysis of genetic aberrations aimed at identifying potential therapeutic targets in fibrolamellar carcinoma of the liver.
El Dika I; Bowman AS; Berger MF; Capanu M; Chou JF; Benayed R; Zehir A; Shia J; O'Reilly EM; Klimstra DS; Solit DB; Abou-Alfa GK
Cancer; 2020 Sep; 126(18):4126-4135. PubMed ID: 32663328
[TBL] [Abstract][Full Text] [Related]
6. GalNAc-conjugated siRNA targeting the DNAJB1-PRKACA fusion junction in fibrolamellar hepatocellular carcinoma.
Neumayer C; Ng D; Requena D; Jiang CS; Qureshi A; Vaughan R; Prakash TP; Revenko A; Simon SM
Mol Ther; 2024 Jan; 32(1):140-151. PubMed ID: 37980543
[TBL] [Abstract][Full Text] [Related]
7. Oncogenic Addiction of Fibrolamellar Hepatocellular Carcinoma to the Fusion Kinase DNAJB1-PRKACA.
Neumayer C; Ng D; Jiang CS; Qureshi A; Lalazar G; Vaughan R; Simon SM
Clin Cancer Res; 2023 Jan; 29(1):271-278. PubMed ID: 36302174
[TBL] [Abstract][Full Text] [Related]
8. Fibrolamellar Carcinoma: Recent Advances and Unresolved Questions on the Molecular Mechanisms.
Lalazar G; Simon SM
Semin Liver Dis; 2018 Feb; 38(1):51-59. PubMed ID: 29471565
[TBL] [Abstract][Full Text] [Related]
9. FusionVAC22_01: a phase I clinical trial evaluating a DNAJB1-PRKACA fusion transcript-based peptide vaccine combined with immune checkpoint inhibition for fibrolamellar hepatocellular carcinoma and other tumor entities carrying the oncogenic driver fusion.
Hackenbruch C; Bauer J; Heitmann JS; Maringer Y; Nelde A; Denk M; Zieschang L; Kammer C; Federmann B; Jung S; Martus P; Malek NP; Nikolaou K; Salih HR; Bitzer M; Walz JS
Front Oncol; 2024; 14():1367450. PubMed ID: 38606105
[TBL] [Abstract][Full Text] [Related]
10. The oncogenic fusion protein DNAJB1-PRKACA can be specifically targeted by peptide-based immunotherapy in fibrolamellar hepatocellular carcinoma.
Bauer J; Köhler N; Maringer Y; Bucher P; Bilich T; Zwick M; Dicks S; Nelde A; Dubbelaar M; Scheid J; Wacker M; Heitmann JS; Schroeder S; Rieth J; Denk M; Richter M; Klein R; Bonzheim I; Luibrand J; Holzer U; Ebinger M; Brecht IB; Bitzer M; Boerries M; Feucht J; Salih HR; Rammensee HG; Hailfinger S; Walz JS
Nat Commun; 2022 Oct; 13(1):6401. PubMed ID: 36302754
[TBL] [Abstract][Full Text] [Related]
11. CRISPR/Cas9 Engineering of Adult Mouse Liver Demonstrates That the Dnajb1-Prkaca Gene Fusion Is Sufficient to Induce Tumors Resembling Fibrolamellar Hepatocellular Carcinoma.
Engelholm LH; Riaz A; Serra D; Dagnæs-Hansen F; Johansen JV; Santoni-Rugiu E; Hansen SH; Niola F; Frödin M
Gastroenterology; 2017 Dec; 153(6):1662-1673.e10. PubMed ID: 28923495
[TBL] [Abstract][Full Text] [Related]
12. DNAJB1-PRKACA is specific for fibrolamellar carcinoma.
Graham RP; Jin L; Knutson DL; Kloft-Nelson SM; Greipp PT; Waldburger N; Roessler S; Longerich T; Roberts LR; Oliveira AM; Halling KC; Schirmacher P; Torbenson MS
Mod Pathol; 2015 Jun; 28(6):822-9. PubMed ID: 25698061
[TBL] [Abstract][Full Text] [Related]
13. DNAJB1-PRKACA fusion neoantigens elicit rare endogenous T cell responses that potentiate cell therapy for fibrolamellar carcinoma.
Kirk AM; Crawford JC; Chou CH; Guy C; Pandey K; Kozlik T; Shah RK; Chung S; Nguyen P; Zhang X; Wang J; Bell M; Mettelman RC; Allen EK; Pogorelyy MV; Kim H; Minervina AA; Awad W; Bajracharya R; White T; Long D; Gordon B; Morrison M; Glazer ES; Murphy AJ; Jiang Y; Fitzpatrick EA; Yarchoan M; Sethupathy P; Croft NP; Purcell AW; Federico SM; Stewart E; Gottschalk S; Zamora AE; DeRenzo C; Strome SE; Thomas PG
Cell Rep Med; 2024 Mar; 5(3):101469. PubMed ID: 38508137
[TBL] [Abstract][Full Text] [Related]
14. Fibrolamellar hepatocellular carcinoma: A rare but unpleasant event.
Abdelhamed W; El-Kassas M
World J Gastrointest Oncol; 2022 Jun; 14(6):1103-1114. PubMed ID: 35949219
[TBL] [Abstract][Full Text] [Related]
15. A framework for fibrolamellar carcinoma research and clinical trials.
Dinh TA; Utria AF; Barry KC; Ma R; Abou-Alfa GK; Gordan JD; Jaffee EM; Scott JD; Zucman-Rossi J; O'Neill AF; Furth ME; Sethupathy P
Nat Rev Gastroenterol Hepatol; 2022 May; 19(5):328-342. PubMed ID: 35190728
[TBL] [Abstract][Full Text] [Related]
16. Successful Liver Transplantation of Recurrent Fibrolamellar Carcinoma following Clinical and Pathologic Complete Response to Triple Immunochemotherapy: A Case Report.
Kang S; Magliocca J; Sellers M; Roccaro G; Zheng W; Pectasides M; Draper A; Guadagno J; El-Rayes B; Akce M
Oncol Res Treat; 2022; 45(7-8):430-437. PubMed ID: 35537414
[TBL] [Abstract][Full Text] [Related]
17. Fibrolamellar carcinoma in the Carney complex: PRKAR1A loss instead of the classic DNAJB1-PRKACA fusion.
Graham RP; Lackner C; Terracciano L; González-Cantú Y; Maleszewski JJ; Greipp PT; Simon SM; Torbenson MS
Hepatology; 2018 Oct; 68(4):1441-1447. PubMed ID: 29222914
[TBL] [Abstract][Full Text] [Related]
18. DNAJB1-PRKACA fusion protein-regulated LINC00473 promotes tumor growth and alters mitochondrial fitness in fibrolamellar carcinoma.
Ma RK; Tsai PY; Farghli AR; Shumway A; Kanke M; Gordan JD; Gujral TS; Vakili K; Nukaya M; Noetzli L; Ronnekleiv-Kelly S; Broom W; Barrow J; Sethupathy P
PLoS Genet; 2024 Mar; 20(3):e1011216. PubMed ID: 38512964
[TBL] [Abstract][Full Text] [Related]
19. A genomic case study of mixed fibrolamellar hepatocellular carcinoma.
Griffith OL; Griffith M; Krysiak K; Magrini V; Ramu A; Skidmore ZL; Kunisaki J; Austin R; McGrath S; Zhang J; Demeter R; Graves T; Eldred JM; Walker J; Larson DE; Maher CA; Lin Y; Chapman W; Mahadevan A; Miksad R; Nasser I; Hanto DW; Mardis ER
Ann Oncol; 2016 Jun; 27(6):1148-1154. PubMed ID: 27029710
[TBL] [Abstract][Full Text] [Related]
20. DNAJB1-PRKACA-positive metastatic fibrolamellar carcinoma with unknown primary in a pediatric patient.
Balbeur S; Dumortier A; Mergen J; Libbrecht L; Torbenson M; Boulanger C; de Ville de Goyet M; Van Damme A; Brichard B
Pediatr Blood Cancer; 2020 Feb; 67(2):e28060. PubMed ID: 31736218
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
